Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Simply Wall St.06-20

Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644106065?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-20 02:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644106065","market":"hk","top_or_hot":-1,"title":"Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data","media":"Simply Wall St.","content":"<div>\n<p>Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-20 02:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value","article_id":"2644106065","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644106065","pubTimestamp":1781894794,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast cell targeted pipeline.\nSee our latest analysis for Celldex Therapeutics.\nCelldex Therapeutics shares trade at US$32.43, with a year to date share price return of 20.07% and a 1 year total shareholder return of 58.20%. This suggests recent barzolvolimab and CDX-622 data are contributing to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDX":"塞德斯医疗","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"新试验数据公布后，Celldex Therapeutics(CLDX)股价可能比公允价值低61%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":1.5,"DCF":1},"content_text":"Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast cell targeted pipeline. See our latest analysis for Celldex Therapeutics. Celldex Therapeutics shares trade at US$32.43, with a year to date share price return of 20.07% and a 1 year total shareholder return of 58.20%. This suggests recent barzolvolimab and CDX-622 data are contributing to building momentum after weaker multi year returns. If mast cell targeted drugs are on your radar, this is also a useful moment to look across the sector and see what else is developing in allergy and immunology via 41 healthcare AI stocks With Celldex Therapeutics now valued at about US$2.5b and trading at US$32.43, the market has clearly reacted to barzolvolimab and CDX-622 progress. The key question is whether you are looking at an undervalued mast cell platform or a stock already pricing in future growth. AdvertisementPrice-to-Book of 5.6x: Is It Justified for Celldex Therapeutics? Based on the latest data, Celldex Therapeutics trades on a P/B ratio of 5.6x, which looks rich when set against both peers and the wider US Biotechs industry. P/B compares the company’s market value to its net assets on the balance sheet. A higher figure often reflects expectations for future value creation that is not yet visible in current equity. For Celldex Therapeutics, a 5.6x multiple means investors are paying several times the company’s book value for exposure to its mast cell focused pipeline. Against that backdrop, the contrast is clear. Celldex Therapeutics is described as expensive on a P/B basis versus the peer average of 3.6x, and it also screens as expensive relative to the broader US Biotechs industry average of 2.4x. That gap suggests the market is assigning a premium to Celldex’s assets and prospects compared with similar companies in the sector. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 5.6x (OVERVALUED) However, Celldex Therapeutics still faces key risks, including clinical trial setbacks in its mast cell programs and ongoing losses, with revenue of US$865k against net losses of US$283.6m. Find out about the key risks to this Celldex Therapeutics narrative. Another View: Celldex Therapeutics Through a Cash Flow Lens The earlier P/B check describes Celldex Therapeutics as expensive, but the SWS DCF model points in a different direction. With the stock at $32.43 and the model’s future cash flow value at $82.98, it appears significantly undervalued according to this framework. For any reader comparing these two signals, the contrast is clear: one method highlights valuation risk, while the other suggests potential upside based on future cash flows. The core question is which set of assumptions about Celldex Therapeutics’ mast cell pipeline and cash generation potential you find more convincing. Look into how the SWS DCF model arrives at its fair value. CLDX Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed signals around Celldex Therapeutics are clear, so treat this as your prompt to review the data now, weigh both sides, and see the full picture using the 2 key rewards and 3 important warning signs Looking for more investment ideas beyond Celldex Therapeutics? If Celldex Therapeutics has your attention, do not stop there. Broaden your opportunity set and let data driven shortlists surface stocks you might otherwise miss.  Scan for value focused opportunities that combine quality and attractive pricing by reviewing the 45 high quality undervalued stocks. Strengthen your income ideas with a curated set of high yield payers by checking the 8 dividend fortresses. Lower portfolio stress by focusing on stability and resilience with the 66 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644106065","isCrawlerRequest":true}